Jade Biosciences Q1 net loss $40.4M, cash $311.3M; pipeline and CMO appointment

Jade Biosciences, Inc.

2026-Q1 EPS reported -$0.57

Net loss $40.4M for Q1 2026 vs $38.2M in Q1 2025, driven by higher R&D and G&A costs.
Cash, equivalents, and investments $311.3M at March 31, 2026; funding expected into first half 2028.
JADE101 Phase 1 interim biomarker data to be presented at ERA Congress; Phase 2 in IgAN expected Q2 2026.
JADE201 Phase 1 trial in rheumatoid arthritis expected to start Q2 2026; interim data in 2027.
Appointed Edward R. Conner, M.D., as CMO; promoted Andrew King to President, R&D.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Jade Biosciences, Inc. reported the quarter ended March 31, 2026 results: net income Net loss totaled $40.4 million for the first quarter ended March 31, 2026.

Period: the quarter ended March 31, 2026
Net income: Net loss totaled $40.4 million for the first quarter ended March 31, 2026
Result: reported results

Exact text from the filing

On May 7, 2026, Jade Biosciences, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the quarter ended March 31, 2026.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Jade Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-211973

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.